pd 98059 has been researched along with Cancer of Liver in 38 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After DEN-induced hepatocellular carcinoma (HCC) in rats showed increased phosphorylation of JNK1/2, p38, and ERK1/2, we next antagonized TGF-β1-induced phosphorylation of JNK1/2, p38, ERK1/2, Smad2/3 signaling in HepG2 cells using SP600125, SB203580, and PD98059, respectively." | 1.42 | MAPK inhibitors differently modulate TGF-β/Smad signaling in HepG2 cells. ( Boye, A; He, S; Jiang, Y; Kan, H; Wu, C; Yang, X; Yang, Y, 2015) |
| "Human hepatocellular carcinoma (HCC) cell lines SMMC7721 and Huh7 were used." | 1.39 | Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. ( Ding, X; Dong, S; Gao, J; Ke, S; Kong, F; Kong, J; Sun, W; Wang, S; Zheng, L, 2013) |
| "TRAIL-induced apoptosis of hepatocellular carcinoma cells (HuH-7, Hep3B) was associated with lysosomal permeabilization, as demonstrated by redistribution of the lysosomal protease cathepsin B into the cytosol." | 1.34 | cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. ( Bronk, SF; Gores, GJ; Guicciardi, ME; Werneburg, NW, 2007) |
| "Overexpressing MHBs(t) in hepatoma cells enhanced TRAIL-induced apoptosis." | 1.34 | The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2. ( Chen, YH; Cui, M; Du, J; Han, L; Liang, X; Liu, Y; Ma, C; Qu, Z; Sun, W; Sun, Z; Zhang, L; Zhang, Z, 2007) |
| " Contrarily, tumor xenograft P-ERK levels following long-term (24 days) daily dosing of PD184161 were refractory to this signaling effect." | 1.33 | The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. ( Choi, JN; Gage, EA; Klein, PJ; Omer, C; Schmidt, CM; Sebolt-Leopold, JS; Wang, Y; Wiebke, EA; Wiesenauer, CA; Yip-Schneider, MT, 2006) |
| "The human hepatocellular carcinoma (HCC)-derived cell line KYN-2 is thought to provide a good model for studying the molecular basis of invasion and metastasis of human HCC, because it often shows cell scattering in vitro and intrahepatic metastasis in vivo." | 1.33 | MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. ( Aoyagi, Y; Genda, T; Honma, N; Ichida, T; Matsuda, Y; Takamura, M; Yamagiwa, S, 2006) |
| "Human hepatocellular carcinoma (HCC) is associated with increased expression and activity of mitogen-activated protein kinase (MAPK) signaling intermediates (ie, MEK, ERK)." | 1.32 | Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. ( Schmidt, CM; Wang, Y; Wiesenauer, CA; Yip-Schneider, MT, 2004) |
| "Primary cancer of the gallbladder is not unusual." | 1.32 | A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice. ( Ajiki, T; Fujimori, T; Furihata, T; Hori, H; Horiuchi, H; Kawamata, H; Kuroda, Y; Ohkura, Y; Omotehara, F; Shinagawa, Y; Tachibana, M; Yamazaki, T, 2004) |
| "Treatment of human hepatoma (HepG2) and murine hepatoma (Hepa1c1c7) cells with tert-butylhydroquinone (tBHQ) or sulforaphane (SUL), two potent phase II enzyme inducers, stimulated the activity of extracellular signal-regulated protein kinase 2 (ERK2) but not c-Jun N-terminal kinase 1." | 1.30 | Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. ( Der, CJ; Kong, AN; Lei, W; Mandlekar, S; Weber, MJ; Wu, J; Yu, R, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.89) | 18.2507 |
| 2000's | 21 (55.26) | 29.6817 |
| 2010's | 11 (28.95) | 24.3611 |
| 2020's | 3 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 2 |
| Zhou, M | 1 |
| Jin, X | 1 |
| Li, B | 1 |
| Wang, C | 1 |
| Zhang, Q | 1 |
| Liao, M | 1 |
| Hu, X | 1 |
| Yang, M | 1 |
| Li, J | 1 |
| Hu, S | 1 |
| Zhang, Z | 2 |
| Qian, L | 1 |
| Xue, Q | 1 |
| Qu, X | 1 |
| Chen, Z | 1 |
| Chen, L | 4 |
| Sun, B | 1 |
| Liu, D | 1 |
| He, Y | 1 |
| Qi, L | 1 |
| Li, G | 1 |
| Han, Z | 1 |
| Zhan, L | 1 |
| Zhang, S | 1 |
| Zhu, K | 1 |
| Luo, Y | 1 |
| Zhang, N | 1 |
| Guo, H | 1 |
| Sun, J | 1 |
| Luo, Q | 1 |
| Liu, L | 1 |
| Song, G | 1 |
| Dong, S | 1 |
| Kong, J | 2 |
| Kong, F | 1 |
| Gao, J | 1 |
| Ke, S | 1 |
| Wang, S | 1 |
| Ding, X | 1 |
| Sun, W | 3 |
| Zheng, L | 1 |
| Wang, JG | 1 |
| Zheng, XX | 1 |
| Zeng, GY | 1 |
| Zhou, YJ | 1 |
| Yuan, H | 1 |
| Boye, A | 1 |
| Kan, H | 1 |
| Wu, C | 1 |
| Jiang, Y | 1 |
| Yang, X | 2 |
| He, S | 1 |
| Yang, Y | 1 |
| Huang, P | 1 |
| Zhuang, B | 1 |
| Zhang, H | 1 |
| Yan, H | 1 |
| Xiao, Z | 1 |
| Li, W | 1 |
| Zhang, J | 1 |
| Tang, Q | 1 |
| Hu, K | 1 |
| Koeffler, HP | 1 |
| Yin, D | 1 |
| Hong, E | 1 |
| Lee, E | 1 |
| Kim, J | 1 |
| Kwon, D | 1 |
| Lim, Y | 1 |
| Qin, X | 1 |
| Liu, C | 1 |
| Zhou, Y | 1 |
| Wang, G | 1 |
| Lu, JT | 1 |
| Zhao, WD | 1 |
| He, W | 1 |
| Wei, W | 1 |
| Zhou, L | 2 |
| Wang, DS | 1 |
| Li, QJ | 1 |
| Zhang, Y | 3 |
| Dou, KF | 1 |
| Xie, L | 1 |
| Zheng, Y | 1 |
| Li, X | 1 |
| Zhao, J | 1 |
| Chen, X | 2 |
| Zhou, J | 1 |
| Hai, O | 1 |
| Li, F | 1 |
| Wu, R | 1 |
| Duan, L | 1 |
| Ye, L | 1 |
| Wang, H | 1 |
| Weng, Y | 1 |
| Luo, J | 1 |
| Tang, M | 1 |
| Shi, Q | 1 |
| He, T | 1 |
| Seong, J | 1 |
| Kim, SH | 1 |
| Suh, CO | 1 |
| Wen-Sheng, W | 1 |
| Wiesenauer, CA | 2 |
| Yip-Schneider, MT | 2 |
| Wang, Y | 2 |
| Schmidt, CM | 2 |
| Yim, S | 1 |
| Oh, M | 1 |
| Choi, SM | 1 |
| Park, H | 1 |
| Keeton, AB | 1 |
| Xu, J | 1 |
| Franklin, JL | 1 |
| Messina, JL | 1 |
| Tsukada, Y | 2 |
| Tanaka, T | 1 |
| Miyazawa, K | 2 |
| Kitamura, N | 2 |
| Horiuchi, H | 1 |
| Kawamata, H | 1 |
| Furihata, T | 1 |
| Omotehara, F | 1 |
| Hori, H | 1 |
| Shinagawa, Y | 1 |
| Ohkura, Y | 1 |
| Tachibana, M | 1 |
| Yamazaki, T | 1 |
| Ajiki, T | 1 |
| Kuroda, Y | 1 |
| Fujimori, T | 1 |
| Murata, T | 1 |
| Hijikata, M | 1 |
| Shimotohno, K | 1 |
| Li, YL | 1 |
| Chen, XY | 1 |
| Duan, FL | 1 |
| Klein, PJ | 1 |
| Choi, JN | 1 |
| Gage, EA | 1 |
| Wiebke, EA | 1 |
| Omer, C | 1 |
| Sebolt-Leopold, JS | 1 |
| Honma, N | 1 |
| Genda, T | 1 |
| Matsuda, Y | 1 |
| Yamagiwa, S | 1 |
| Takamura, M | 1 |
| Ichida, T | 1 |
| Aoyagi, Y | 1 |
| Tomizawa, M | 1 |
| Saisho, H | 1 |
| Guicciardi, ME | 1 |
| Bronk, SF | 1 |
| Werneburg, NW | 1 |
| Gores, GJ | 1 |
| Liang, X | 1 |
| Du, J | 1 |
| Liu, Y | 1 |
| Cui, M | 1 |
| Ma, C | 1 |
| Han, L | 1 |
| Qu, Z | 1 |
| Sun, Z | 1 |
| Zhang, L | 1 |
| Chen, YH | 1 |
| Elbirt, KK | 1 |
| Whitmarsh, AJ | 1 |
| Davis, RJ | 1 |
| Bonkovsky, HL | 1 |
| Yu, R | 1 |
| Lei, W | 1 |
| Mandlekar, S | 1 |
| Weber, MJ | 1 |
| Der, CJ | 1 |
| Wu, J | 1 |
| Kong, AN | 1 |
| Sipeki, S | 1 |
| Bander, E | 1 |
| Buday, L | 1 |
| Farkas, G | 1 |
| Bácsy, E | 1 |
| Ways, DK | 1 |
| Faragó, A | 1 |
| Baek, JH | 1 |
| Jang, JE | 1 |
| Kang, CM | 1 |
| Chung, HY | 1 |
| Kim, ND | 1 |
| Kim, KW | 1 |
| An, W | 1 |
| Tan, X | 1 |
| Gao, D | 1 |
| Dai, J | 1 |
| Abe, K | 1 |
| Hirai, M | 1 |
| Mizuno, K | 1 |
| Higashi, N | 1 |
| Sekimoto, T | 1 |
| Miki, T | 1 |
| Hirano, T | 1 |
| Nakajima, K | 1 |
| Nijhara, R | 1 |
| Jana, SS | 1 |
| Goswami, SK | 1 |
| Rana, A | 1 |
| Majumdar, SS | 1 |
| Kumar, V | 1 |
| Sarkar, DP | 1 |
| Solorzano, CC | 1 |
| Jung, YD | 1 |
| Bucana, CD | 1 |
| McConkey, DJ | 1 |
| Gallick, GE | 1 |
| McMahon, G | 1 |
| Ellis, LM | 1 |
| Abiru, S | 1 |
| Nakao, K | 1 |
| Ichikawa, T | 1 |
| Migita, K | 1 |
| Shigeno, M | 1 |
| Sakamoto, M | 1 |
| Ishikawa, H | 1 |
| Hamasaki, K | 1 |
| Nakata, K | 1 |
| Eguchi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
38 other studies available for pd 98059 and Cancer of Liver
| Article | Year |
|---|---|
Glycochenodeoxycholate induces cell survival and chemoresistance via phosphorylation of STAT3 at Ser727 site in HCC.
Topics: Carcinoma, Hepatocellular; Cell Survival; Drug Resistance, Neoplasm; Flavonoids; Fluorouracil; Gene | 2020 |
LASP2 is downregulated in human liver cancer and contributes to hepatoblastoma cell malignant phenotypes through MAPK/ERK pathway.
Topics: Carrier Proteins; Cell Movement; Cytoskeletal Proteins; Down-Regulation; Female; Flavonoids; Gene Ex | 2020 |
LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cholesterol; Disease-Free | 2021 |
Low-level shear stress promotes migration of liver cancer stem cells via the FAK-ERK1/2 signalling pathway.
Topics: Cell Movement; Flavonoids; Focal Adhesion Protein-Tyrosine Kinases; Humans; Liver Neoplasms; MAP Kin | 2018 |
Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Chromones; Disease Progress | 2013 |
Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma.
Topics: Apigenin; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Hepatocellular | 2014 |
MAPK inhibitors differently modulate TGF-β/Smad signaling in HepG2 cells.
Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Proliferation; Diethylnitrosamine; Flavonoi | 2015 |
Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2015 |
Elevated Pressure Enhanced Trail-Induced Apoptosis in Hepatocellular Carcinoma Cells Via Erk1/2-Inactivation.
Topics: Apoptosis; bcl-Associated Death Protein; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cycl | 2015 |
Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; B7-1 Antigen; B7-H1 Antigen; Carcinoma, Hepatocellular; C | 2010 |
Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway.
Topics: Adult; Aged; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Moveme | 2012 |
Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor.
Topics: Amyloid Precursor Protein Secretases; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Ki | 2012 |
Enhanced proliferation of human hepatoma cells by PAR-2 agonists via the ERK/AP-1 pathway.
Topics: Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Extracellul | 2012 |
S100A9 promotes the proliferation and invasion of HepG2 hepatocellular carcinoma cells via the activation of the MAPK signaling pathway.
Topics: Animals; Calgranulin B; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Transf | 2013 |
Enhancement of radioresponse of murine tumors by ERK inhibitor.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Combined Modality Therapy; Enzyme Inhi | 2002 |
ERK signaling pathway is involved in p15INK4b/p16INK4a expression and HepG2 growth inhibition triggered by TPA and Saikosaponin a.
Topics: Activating Transcription Factor 2; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Division; Cy | 2003 |
Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.
Topics: Apoptosis; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Cell Count; Cell Division; Cell | 2004 |
Inhibition of the MEK-1/p42 MAP kinase reduces aryl hydrocarbon receptor-DNA interactions.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; DNA; Dose-Response Re | 2004 |
Regulation of Gene33 expression by insulin requires MEK-ERK activation.
Topics: Adaptor Proteins, Signal Transducing; Androstadienes; Animals; Carcinoma, Hepatocellular; Carrier Pr | 2004 |
Involvement of down-regulation of Cdk2 activity in hepatocyte growth factor-induced cell cycle arrest at G1 in the human hepatocellular carcinoma cell line HepG2.
Topics: Carcinoma, Hepatocellular; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Ce | 2004 |
A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice.
Topics: Animals; Butadienes; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Flavonoids; Gallbladder Neo | 2004 |
Enhancement of internal ribosome entry site-mediated translation and replication of hepatitis C virus by PD98059.
Topics: Base Sequence; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Hepatocellular; Cell Line, T | 2005 |
[The sensitivity improvement of HBx+HepG2 to CDDP with PD98059].
Topics: Carcinoma, Hepatocellular; Cisplatin; Drug Synergism; Flavonoids; Humans; Liver Neoplasms; Trans-Act | 2005 |
The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzamides; Butadienes; Cell Line, Tumor; Cell Pr | 2006 |
MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells.
Topics: Actin Cytoskeleton; Cadherins; Carcinoma, Hepatocellular; Cell Adhesion; Cell Culture Techniques; Ce | 2006 |
Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma.
Topics: Androstadienes; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; Enzyme Inhibitors; Flavo | 2006 |
cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis.
Topics: Apoptosis; Butadienes; Carcinoma, Hepatocellular; CASP8 and FADD-Like Apoptosis Regulating Protein; | 2007 |
The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Enzyme Activation; Enzyme | 2007 |
Mechanism of sodium arsenite-mediated induction of heme oxygenase-1 in hepatoma cells. Role of mitogen-activated protein kinases.
Topics: Animals; Arsenites; Cadmium; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Hepatocellular | 1998 |
Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Enzyme Induction; Enzyme Inhibitors; Flav | 1999 |
Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering.
Topics: Carcinoma, Hepatocellular; Cell Movement; Chromones; Cycloheximide; Enzyme Inhibitors; Flavonoids; H | 1999 |
Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis.
Topics: Apoptosis; Autocrine Communication; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 3 | 2000 |
Phosphorylation of hepatic stimulator substance on mitogen-activated protein kinase in BEL-7402 hepatoma cells.
Topics: Animals; Carcinoma, Hepatocellular; ErbB Receptors; Flavonoids; Growth Substances; Intercellular Sig | 2001 |
The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 3T3 Cells; Alanine; Amino Acid Sequence; Amino Acid S | 2001 |
High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2.
Topics: Base Sequence; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; DNA Primers; Enzyme Inhibitors; | 2001 |
Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo.
Topics: Animals; Carcinoma, Hepatocellular; DNA, Viral; Enzyme Activation; Female; Flavonoids; Hepatocytes; | 2001 |
In vivo intracellular signaling as a marker of antiangiogenic activity.
Topics: Androstadienes; Angiogenesis Inhibitors; Biomarkers, Tumor; Blotting, Western; Endothelial Growth Fa | 2001 |
Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Cyclooxygenase 2; Cyclo | 2002 |